Creative Biolabs, Your Immuno-Oncology Partner
Looking for partners to facilitate your research in immuno-oncology? With over 12 years of expertise in therapeutic antibody discovery and development, Creative Biolabs has established itself as a leader in contract research organization (CRO), providing comprehensive services from target selection to IND regulatory approval. With advanced platforms for antibody engineering, production, and testing, along with strong regulatory knowledge, we ensure efficient project execution. Our innovative Next-IO™ programs focus on immune-targeting therapies, and we guarantee full intellectual property rights for clients.
With over 12 years of innovation, Creative Biolabs has established itself as a leading contract research organization (CRO) specializing in the discovery and development of therapeutic antibodies, including monoclonal and bispecific antibodies. Our experience spans various indications, focusing on cancer treatments and unmet medical needs. Backed by senior scientists with more than 10 years of experience, we provide state-of-the-art end-to-end solutions, guiding clients from target selection to IND regulatory approval.
Creative Biolabs offers a streamlined process that covers every step of the antibody drug development process, from discovery to production. We are also proficient in providing single-tailored biological testing to meet your specific needs. Our regulatory expertise ensures that clients receive fully compliant data within the promised timelines, helping to accelerate the drug discovery process. Our services include but not limited to:
The Next-IO™ programs focus on developing novel therapeutic antibodies targeting the immune system, including T cells, B cells, NK cells, dendritic cells, and macrophages. These innovative programs aim to develop effective treatments for cancer through advanced strategies and collaboration.
| Programs | Related Cells/Antigens | Examples | |
|---|---|---|---|
| ImmuneSystem Cells | Next-IO™ APC-Related Therapeutics | APC |
Anti-CD40 Anti-CD70 Anti-OX40L |
| Next-IO™ T Cell-Related Therapeutics | T Cell |
Anti-FGL1 Anti-Siglec-15 Anti-TIM3 Anti-4-1BB |
|
| Next-IO™ NK Cell-Related Therapeutics | NK Cell |
Fusion Protein of NKG2D Anti-sMIC Anti-CD48 |
|
| Next-IO™ B Cell-related Therapeutics | B Cell | In development | |
| Next-IO™ Macrophages-Related Therapeutics | Macrophage | TAM-Related | |
| Tumor | Next-IO™ Tumor-Associated Antigens | Tumor-Associated Antigens |
Anti-CD73 Anti-GPVI Anti-Phosphatidylserine |
| COVID-19 Recovered Patient-Derived Anti-SARS-CoV-2 Therapeutic Antibody Development | COVID-19 Patient-Derived cells | Anti-SARS-CoV-2 |
We ensure that clients have full intellectual property rights and ownership of all therapeutic antibodies and proteins developed. Creative Biolabs guarantees complete support in managing risks, allowing clients to lead the process with peace of mind.
Creative Biolabs actively seeks collaborative partnerships for co-developing programs from the discovery phase to IND enabling. We offer flexible collaboration models, including shared development costs or licensing opportunities for commercial partners. Our strong quality control protocols and understanding of global regulatory requirements help bring projects to market efficiently.
With over several years of expertise in therapeutic antibody discovery and development, Creative Biolabs has partnered with many leading enterprises to facilitate their discovery of innovative medicines. We provide comprehensive services including antibody discovery, engineering, production, and testing with our advanced Next-IO™ Programs. If you want to know more details of our services, please do not hesitate to contact us!
Trust Creative Biolabs to deliver tailored solutions, offering precise and actionable insights to support every step of your immuno-oncology research journey.